Ambry Genetics
For most of humanity’s existence, we had only one way to make babies. The last century or so have seen the beginnings of change, with artificial insemination, in vitro fertilization, and prenatal and preimplantation genetic testing. The rest of this century will see astonishing changes, made both possible and attractive by genomics – from embryo selection to embryo editing, from mitochondrial transfer to human reproductive cloning, to in vitro gametogenesis, and beyond. This talk will survey those changes and point out some of their likely ethical, legal, and social implications.
Watch Now
solvobiotech
Transporters are involved in clinically significant drug-drug interactions (DDI). Such interactions can occur at multiple sites, including in organs important in drug absorption (e.g. intestine), elimination (e.g. liver and kidneys) and distribution (e.g. brain). Notably, some of these interactions can be “hidden”, occurring in a tissue with no discernible trace in the systemic circulation. In addition, for drugs that are both transported and metabolized, DDI will most prominent when they occur at the “rate-limiting step” in the clearance of the drug.
Watch Now
Autoantibody assays may have significant differences due to the heterogeneity of autoantibodies, including epitope specificity, isotype, and affinity/avidity.
Watch Now
Developing new CRISPR/Cas9-based genome editing tools will enhance innovative therapeutic products and the pathway to clinical programs. However, current obstacles in genome editing include high error rates, toxicity from production impurities, and strict regulatory concerns.
Watch Now